Gamida Cell Ltd. - Ordinary Shares (GMDA) News
Filter GMDA News Items
GMDA News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
Latest GMDA News From Around the Web
Below are the latest news stories about GAMIDA CELL LTD that investors may wish to consider to help them evaluate GMDA as an investment opportunity.
Gamida Cell to Host Virtual Thought Leader Fireside Chat on December 4, 2023BOSTON, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, is hosting a virtual fireside chat with thought leader Gary Schiller, MD, FACP, Professor of Medicine and Director of the Hematological Malignancy & Stem Cell Transplant Program at the David Geffen School of Medicine at University of California – Los Angeles. Dr. Schiller will discuss his experience working with patients in need of allogeneic stem ce |
Gamida Cell to Present Corporate Highlights at the Piper Sandler 35th Annual Healthcare ConferenceBOSTON, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that its management team will present corporate highlights at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, NY. Presentation Details Format:Fireside ChatDate/Time:Tuesday, November 28, 2023 at 11:00 –11:25 AM ETWebcast:Click here. The Gamida Cell management team will be available for one-on-one meetings dur |
Gamida Cell Ltd. (NASDAQ:GMDA) Q3 2023 Earnings Call TranscriptGamida Cell Ltd. (NASDAQ:GMDA) Q3 2023 Earnings Call Transcript November 14, 2023 Gamida Cell Ltd. beats earnings expectations. Reported EPS is $-0.01, expectations were $-0.15. Operator: Ladies and gentlemen, thank you for standing by. Welcome to Gamida Cell’s Conference Call for Third Quarter 2023 Financial Results. My name is Chris, and I’ll be your operator […] |
Q3 2023 Gamida Cell Ltd Earnings CallQ3 2023 Gamida Cell Ltd Earnings Call |
Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company UpdateCompany continues to advance launch, reports initial revenue from Omisirge® (omidubicel-onlv) Company to host conference call today at 8:30 a.m. ET BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today reported financial results for the quarter ended September 30, 2023, and provided a business update. “The third quarter marked the first patients receiving Omisirge following FDA approval and the po |
Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer (SITC) Annual MeetingData further characterize the mechanism for Gamida Cell’s proprietary nicotinamide (NAM) technology’s expansion and enhancement of cellsBOSTON, Nov. 04, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today shared new data on the impact of the company’s proprietary nicotinamide (NAM) technology on its allogeneic stem cell therapy omidubicel and investigational natural killer (NK) cell therapy candidate GDA-201 at |
Gamida Cell to Report Third Quarter 2023 Financial ResultsBOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will release its financial results for the third quarter ended September 30, 2023 and provide an update on the company on Tuesday, November 14, 2023. Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide business updates and ans |
Gamida Cell Reports Preliminary Data from Phase 1 Study of Natural Killer (NK) Cell Therapy Candidate GDA-201BOSTON, October 16, 2023--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced new early data in 10 patients with CD20 positive non-Hodgkin lymphoma enrolled in the first three cohorts in an ongoing multicenter Phase 1 study of natural killer (NK) cell therapy candidate GDA-201. The study is designed to evaluate safety and determine the maximum tolerated dose. |
Gamida Cell Issues Update on Israel OperationsBOSTON, October 09, 2023--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today issued an update on its operations in Israel. |
Gamida Cell to Present Corporate Highlights at 2023 Cell & Gene Meeting on the MesaBOSTON, October 02, 2023--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that Abbey Jenkins, President and Chief Executive Officer, will present its corporate highlights at the annual Cell & Gene Meeting on the Mesa to be held October 10-12 in Carlsbad, California, and livestreamed globally. Ms. Jenkins will also participate in a panel titled "A record setting year for cell and gene therapies – how do we keep the momentum |